Nexus BioQuest is a leading immunology focused contract research organisation (CRO) delivering bespoke preclinical research services that support the development of next generation therapies. Founded in 2022, we have rapidly grown into a trusted partner for biotechnology and pharmaceutical companies across the UK, USA, Europe and beyond. Our mission is to accelerate the development of new medicines by combining deep immunological insight, scientific excellence, and an agile, collaborative approach.
We specialise in immune-modulating therapies and offer a wide range of high-value services including bespoke assay development, validated preclinical and non regulatory clinical assays, and functional biomarker discovery. Our scientific programmes span key therapeutic areas such as immune oncology, autoimmunity, inflammation, neuroinflammation and vaccines. We work across diverse therapeutic formats including small molecules, biologics, cell and gene therapies, and combination treatments. All client engagement is led by people who are scientists, ensuring projects are built around real scientific understanding from the outset.
What sets us apart is our ability to offer the scientific depth of a large CRO with the speed and flexibility of a specialist team. Our clients value our hands-on, consultative approach and our ability to turn around high quality data quickly, helping them move efficiently from discovery to decision.
